CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic landscape of lymphoma ...

This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community care These data demonstrate Roche's commitment to providing options ...

Although the mother and her breastmilk tested positive for CAR T cells, the baby did not, showing only normal T- and B-cell subsets.

In this video, Paolo F. Caimi, MD, MBA, discusses research evaluating whether multi-virus specific T-cells could enhance ...

A research team has discovered a previously unknown mechanism that could explain why many patients with aggressive B-cell ...

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

Researchers sought to determine whether CD19-targeting CAR-T therapy would be an effective therapy for patients with relapsed/refractory LBCL.